Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
Ibrahim, S
Pharmacologic treatment of obesity in adults
directly compared GLP-1 receptor agonists to insulin or sulfonylureas, whereas Chang et al
Large clinical trials have not identified bone loss as a significant adverse effect, though the weight loss these medications produce may indirectly affect bone density in some individuals
1) revealed substitutions at the known DPP-4 cleavage site (Ala 8 in human) to Ser or Phe in platypus and echidna respectively, predicting that DPP-4 cleavage could be affected
US$ 22.83
US$ 26.43
US$ 23.47
US$ 25.21
US$ 20.90
US$ 24.86
US$ 28.44
US$ 27.93
US$ 22.23
US$ 24.80
US$ 24.23
US$ 25.54
US$ 24.10
